Associated tags: Plaque, IVL, Cardiovascular disease, Animation, Medicine, Moyamoya disease, Shock wave, Pharmaceutical industry, Patient
Locations: EUROPE, NV, BOSTON, MA, SPAIN, LONDON, NEW YORK, NY, NEW ZEALAND, UNITED KINGDOM, USA, LATIN AMERICA, NEW JERSEY, SANTA CLARA, CA, US, UNITED STATES, NORTH AMERICA, CALIFORNIA, EUROPEAN UNION
Observational study,
Cardiovascular disease,
University Medical Center,
Patient,
Angina,
Șaeș,
CCS,
American College,
University Medical Center Utrecht,
DRS,
Royal Brompton Hospital,
MACE,
Pharmaceutical industry These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.
Key Points:
- These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.
- Results were presented earlier today at the 73rd Annual Scientific Sessions of the American College of Cardiology in Atlanta, GA.
REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
- “Results from the REDUCER-I study continue to demonstrate the safety and effectiveness of Shockwave Coronary Sinus Reducer as a novel therapy for refractory angina,” said Dr. Verheye.
- Results from COSIRA-II are intended to support the regulatory filing for US FDA approval of Shockwave Reducer.
SANTA CLARA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from Monday, April 8 to Thursday, April 11, 2024.
Key Points:
- SANTA CLARA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from Monday, April 8 to Thursday, April 11, 2024.
- Shockwave’s management is scheduled for a live fireside chat on Tuesday, April 9, 2024, at 8:45 a.m. Eastern Time.
- Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at: https://ir.shockwavemedical.com .
Research,
Medical Devices,
Health Technology,
Cardiology,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Science,
Cardiovascular disease,
Worldwide,
Growth,
Peripheral artery disease,
Coronary artery disease,
Johnson & Johnson,
Patient,
PAD,
JNJ,
Perella Weinberg Partners,
Acquisition,
Electrophysiology,
Death,
IVL,
Medtech,
Ventricular fibrillation,
European,
PCI,
Artery,
Laminar,
Stenosis,
Hand,
Physician,
Percutaneous coronary intervention,
CAD,
Pharmaceutical industry Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
Key Points:
- Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
- The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.
- Delivers immediate operational accretion: The transaction will be accretive to operating margin for both Johnson & Johnson and Johnson & Johnson MedTech.
- Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash through a merger of Shockwave with a wholly owned Johnson & Johnson subsidiary.
Acquisition,
IVL,
Investment,
Physician,
Cardiovascular disease,
Growth,
Adjustment,
CPT,
Piping and plumbing fitting,
Patient,
Remuneration,
Video game Gross profit for the fourth quarter of 2023 was $177.7 million compared to $126.5 million for the corresponding prior year period.
Key Points:
- Gross profit for the fourth quarter of 2023 was $177.7 million compared to $126.5 million for the corresponding prior year period.
- Gross margin for the fourth quarter of 2023 was 88%, consistent with 88% for the corresponding prior year period.
- Adjusted EBITDA was $68.2 million in the fourth quarter of 2023, a 20% increase compared to adjusted EBITDA of $56.6 million in the fourth quarter of 2022.
- Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Thursday, February 15, 2024, to discuss its fourth quarter and full year 2023 financial results.
Patient,
Therapy,
Health,
CFO,
Certified Public Accountant,
IVL,
Loyola Marymount University,
Bachelor of Science,
Cardiovascular disease,
Growth,
Management SANTA CLARA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective February 5, 2024.
Key Points:
- SANTA CLARA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective February 5, 2024.
- Renee succeeds Dan Puckett, CFO at Shockwave since 2016, who previously announced his decision to retire.
- “Renee is a highly skilled and accomplished executive with a proven track record in the medical device and healthcare industries,” said Doug Godshall, Chief Executive Officer at Shockwave.
- “I am thrilled to welcome Renee to Shockwave and look forward to partnering with her through our next phase of growth and profitability.
SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates:
Key Points:
- SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates:
Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET)
First Quarter 2024 Earnings – Monday, May 6, 2024 at 4:30 p.m. (ET)
Second Quarter 2024 Earnings – Monday, August 5, 2024 at 4:30 p.m. (ET)
Third Quarter 2024 Earnings – Monday, November 4, 2024 at 4:30 p.m. (ET)
Investors interested in listening to the fourth quarter 2023 earnings conference call at 4:30 p.m. eastern time on Thursday, February 15, 2024, may do so by dialing (877) 704-4453 for domestic callers or (201) 389-0920 for international callers, using conference ID: 13742096.
- Live and archived webcasts of all earnings events will also be made available at https://ir.shockwavemedical.com .
- Dial-in information for future earnings calls will be provided at later dates.
SANTA CLARA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, which is being held from Monday, January 8 to Thursday, January 11, 2024, in San Francisco, CA.
Key Points:
- SANTA CLARA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, which is being held from Monday, January 8 to Thursday, January 11, 2024, in San Francisco, CA.
- Shockwave management is scheduled for a live presentation on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time.
- Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at: https://ir.shockwavemedical.com .
SANTA CLARA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th Annual Healthcare Conference, which is being held from Tuesday, November 28 to Thursday, November 30, 2023 in New York, NY.
Key Points:
- SANTA CLARA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th Annual Healthcare Conference, which is being held from Tuesday, November 28 to Thursday, November 30, 2023 in New York, NY.
- Shockwave management is scheduled for a live fireside chat on Wednesday, November 29, 2023, at 1:30 p.m. Eastern Time.
- Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at: https://ir.shockwavemedical.com .
Yale School of Medicine,
CAD,
IV,
Treatment,
Coronary artery disease,
Dissection,
Doctor of Philosophy,
IVL,
Journal,
St. Francis Hospital,
TLF,
MACE,
HR,
Perforation,
CT,
Woman,
Safety,
Society,
USE,
Hospital,
Reflow soldering,
EMPOWER,
Cardiovascular disease,
Pharmaceutical industry,
Birth control,
MD,
Cardiology The one-year results from Disrupt CAD III and IV trials were recently published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) .
Key Points:
- The one-year results from Disrupt CAD III and IV trials were recently published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) .
- In the patient-level pooled analysis, titled “Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes,” use of IVL for lesion preparation of severely calcified lesions had similar safety and effectiveness in women and men at a one-year follow-up.
- At one-year, major adverse cardiovascular event (MACE) rates were not different between women and men (12.3% vs 13.2%, p=0.52) and there was no difference between women and men in target lesion failure (TLF, 10.4% vs. 11.2% p=0.43).
- The European lead is Nieves Gonzalo, MD, PhD, Consultant Interventional Cardiologist at Hospital Clinico San Carlos in Madrid, Spain.
Medicare,
Physician,
RVU protocol,
EBITDA,
PFS,
Shock wave,
IVL,
United,
Remuneration,
Centers for Medicare & Medicaid Services,
Growth,
Investment,
Patient,
CMS,
Cardiovascular disease,
Video game,
Pharmaceutical industry SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended September 30, 2023.
Key Points:
- SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended September 30, 2023.
- Gross profit for the third quarter of 2023 was $161.5 million compared to $113.5 million for the third quarter of 2022.
- Total operating expenses for the third quarter of 2023 were $117.9 million, a 54% increase from $76.7 million in the third quarter of 2022.
- Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, November 6, 2023, to discuss its third quarter 2023 financial results.
